Market Summary
USD58.56+0.50
Market Closed0.86%
INCY Alerts
INCY Stock Price
INCY RSI Chart
INCY Valuation
INCY Price/Sales (Trailing)
INCY Profitability
INCY Fundamentals
INCY Revenue
INCY Earnings
Price Action
52 Week Range
56.8286.29
(Low)(High)
Last 7 days
-1.2%
Last 30 days
-10.2%
Last 90 days
-6.5%
Trailing 12 Months
-12.9%
INCY Financial Health
INCY Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for INCY
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-01 | SWAIN PAULA J | sold | -550,283 | 65.13 | -8,449 | evp, human resources |
2023-08-01 | Stein Steven H | sold | -1,361,220 | 63.28 | -21,511 | evp & chief medical officer |
2023-07-14 | Stamoulis Christiana | acquired | - | - | 12,246 | evp & chief financial officer |
2023-07-14 | Tray Thomas | acquired | - | - | 6,015 | principal accounting officer |
2023-07-14 | Dhanak Dashyant | acquired | - | - | 8,056 | evp & chief scientific officer |
2023-07-14 | Hoppenot Herve | acquired | - | - | 43,184 | chairman / ceo |
2023-07-14 | CAGNONI PABLO J | acquired | - | - | 9,668 | president, r&d |
2023-07-14 | Stein Steven H | acquired | - | - | 13,535 | evp & chief medical officer |
2023-07-14 | Iyengar Vijay K | acquired | - | - | 7,089 | evp, gmapps |
2023-07-14 | SWAIN PAULA J | acquired | - | - | 7,089 | evp, human resources |
Which funds bought or sold INCY recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-21 | Jefferies Group LLC | new | - | 6,664,000 | 6,664,000 | 0.06% |
2023-09-21 | Baystate Wealth Management LLC | unchanged | - | -200 | 1,245 | -% |
2023-09-20 | BARCLAYS PLC | reduced | -11.72 | -8,053,000 | 25,569,000 | 0.02% |
2023-09-12 | Farther Finance Advisors, LLC | reduced | -48.15 | -2,160 | 1,743 | -% |
2023-08-25 | Yarbrough Capital, LLC | unchanged | - | -49,999 | 310,628 | 0.02% |
2023-08-24 | Alberta Investment Management Corp | reduced | -21.85 | -2,582,790 | 5,320,010 | 0.05% |
2023-08-22 | Old North State Trust, LLC | sold off | -100 | -1,000 | - | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | reduced | -28.89 | -949,979 | 1,501,780 | 0.01% |
2023-08-22 | COMERICA BANK | new | - | - | - | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 65.25 | 613,474 | 2,064,130 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
INCY Alerts
Schedule 13G FIlings of Incyte
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Jun 08, 2023 | blackrock inc. | 10.5% | 23,468,952 | SC 13G/A | |
| Mar 15, 2023 | baker bros. advisors lp | 16.3% | 36,280,967 | SC 13D/A | |
| Feb 14, 2023 | dodge & cox | 8.7% | 19,362,935 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.68% | 21,533,818 | SC 13G/A | |
| Jan 25, 2023 | blackrock inc. | 8.9% | 19,836,617 | SC 13G/A | |
| Mar 10, 2022 | baker bros. advisors lp | 16.4% | 36,269,307 | SC 13D/A | |
| Feb 14, 2022 | baker bros. advisors lp | 15.7% | 34,851,571 | SC 13D/A | |
| Feb 14, 2022 | price t rowe associates inc /md/ | 3.2% | 7,271,688 | SC 13G/A | |
| Feb 14, 2022 | dodge & cox | 7.5% | 16,657,586 | SC 13G | |
| Feb 10, 2022 | vanguard group inc | 9.48% | 20,944,759 | SC 13G/A |
Recent SEC filings of Incyte
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 12, 2023 | 8-K | Current Report | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 01, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 14, 2023 | SC 13D/A | 13D - Major Acquisition | |
| Aug 03, 2023 | 4 | Insider Trading | |
| Aug 01, 2023 | 10-Q | Quarterly Report | |
| Aug 01, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 01, 2023 | 8-K | Current Report | |
| Jul 18, 2023 | 4 | Insider Trading | |
| Jul 18, 2023 | 4 | Insider Trading |
INCY Fair Value
Loading...
Peers (Alternatives to Incyte)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
GILD | 92.4B | 27.4B | -3.33% | 22.27% | 16.85 | 3.37 | -0.48% | 32.56% |
MRNA | 39.4B | 10.7B | -8.22% | -12.63% | 32.61 | 3.69 | -53.67% | -91.41% |
INCY | 13.0B | 3.5B | -10.25% | -12.88% | 35.38 | 3.69 | 5.81% | -61.22% |
EXAS | 12.0B | 2.3B | -21.99% | 104.46% | -27.78 | 5.21 | 18.69% | 41.23% |
| MID-CAP | ||||||||
EXEL | 7.1B | 1.7B | -2.29% | 41.71% | 43.33 | 4.15 | 10.25% | -39.75% |
SYNH | 4.5B | 5.4B | 1.03% | -7.57% | 62.57 | 0.82 | 0.01% | -74.39% |
ARWR | 2.8B | 256.2M | -6.12% | -20.57% | -15.52 | 10.97 | 2.51% | -17.66% |
DNLI | 2.7B | - | -15.10% | -35.52% | -21.18 | 37.44 | 122.90% | 54.78% |
| SMALL-CAP | ||||||||
NVAX | 668.6M | 1.6B | -13.64% | -61.04% | -1.14 | 0.42 | 23.74% | 60.24% |
AVXL | 517.6M | - | -19.90% | -38.37% | -10.02 | 6.7K | - | -13.75% |
PGEN | 329.6M | 22.1M | -28.73% | -39.15% | 14.88 | 14.91 | 43.14% | 124.16% |
SRNE | 170.9M | 66.2M | -71.28% | -88.95% | -0.25 | 2.73 | 20.37% | -7.56% |
NNVC | 15.7M | - | -6.90% | -21.97% | -2.32 | - | - | 19.06% |
TENX | 7.1M | 559.4K | -13.48% | -91.21% | -0.37 | 12.75 | - | 69.86% |
Incyte News
Returns for INCY
Cumulative Returns on INCY
3.8%
10-Year Cumulative Returns
-6.9%
7-Year Cumulative Returns
-3.6%
5-Year Cumulative Returns
-13.2%
3-Year Cumulative Returns
Risks for INCY
What is the probability of a big loss on INCY?
74.2%
Probability that Incyte stock will be more than 20% underwater in next one year
14.6%
Probability that Incyte stock will be more than 30% underwater in next one year.
1.5%
Probability that Incyte stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does INCY drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Incyte was unfortunately bought at previous high price.
Drawdowns
Financials for Incyte
Income Statement (Last 12 Months)(In Thousands)
| Income Statement (Last 12 Months) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 1.2% | 3,513,286 | 3,470,073 | 3,394,635 | 3,330,788 | 3,320,472 | 3,114,784 | 2,986,267 | 2,912,923 | 2,720,579 | 2,702,913 | 2,666,702 | 2,456,582 | 2,387,520 | 2,229,409 | 2,158,759 | 2,107,772 | 2,005,874 | 1,997,458 | 1,881,883 | 1,797,637 | 1,729,488 |
| Costs and Expenses | 3.5% | 3,086,267 | 2,982,403 | 2,815,195 | 2,710,707 | 2,603,357 | 2,511,264 | 2,400,490 | 2,273,651 | 2,311,391 | 2,203,788 | 2,930,378 | 2,789,479 | 2,591,427 | 2,565,477 | 1,756,753 | 1,718,799 | 1,720,098 | 1,727,055 | 1,752,660 | 1,882,807 | 1,830,758 |
| S&GA Expenses | 2.8% | 1,138,814 | 1,108,162 | 1,002,140 | 955,523 | 879,767 | 795,349 | 739,560 | 680,346 | 610,430 | 559,569 | 516,922 | 486,111 | 467,931 | 455,876 | 468,711 | 440,892 | 434,806 | 436,892 | 434,407 | 423,775 | 418,518 |
| R&D Expenses | 3.3% | 1,692,758 | 1,639,204 | 1,585,936 | 1,557,403 | 1,508,341 | 1,504,656 | 1,458,179 | 1,391,297 | 1,494,461 | 1,437,551 | 2,215,942 | 2,122,864 | 1,966,091 | 1,968,853 | 1,154,111 | 1,145,482 | 1,156,673 | 1,165,399 | 1,197,957 | 1,340,590 | 1,317,620 |
| EBITDA | -100.0% | - | 583,520 | 599,637 | 635,767 | 694,445 | 634,330 | 630,196 | 676,262 | 461,648 | 595,658 | -178,237 | -219,977 | -67,484 | -265,520 | 543,179 | - | - | - | - | - | - |
| EBITDA Margin | -100.0% | - | 0.17* | 0.18* | 0.19* | 0.21* | 0.20* | 0.21* | 0.23* | 0.17* | 0.22* | -0.07* | -0.09* | -0.03* | -0.12* | 0.25* | - | - | - | - | - | - |
| Interest Expenses | -0.9% | 2,432 | 2,455 | 2,666 | 2,751 | 2,549 | 2,229 | 1,908 | 1,584 | 1,689 | 1,931 | 2,174 | 2,353 | 2,406 | 2,122 | 1,855 | 1,603 | 1,411 | 1,493 | 1,543 | 1,561 | 1,360 |
| Earnings Before Taxes | 9.4% | 558,663 | 510,437 | 529,116 | 568,521 | 629,402 | 571,657 | 570,444 | 618,526 | 405,549 | 541,180 | -232,218 | -274,316 | -122,789 | -321,382 | 486,791 | 431,504 | 314,461 | 259,798 | 115,347 | -103,647 | -91,269 |
| EBT Margin | -100.0% | - | 0.15* | 0.16* | 0.17* | 0.19* | 0.18* | 0.19* | 0.21* | 0.15* | 0.20* | -0.09* | -0.11* | -0.05* | -0.14* | 0.23* | - | - | - | - | - | - |
| Net Income | 13.0% | 366,487 | 324,371 | 340,660 | 876,050 | 945,014 | 933,038 | 948,581 | 534,580 | 337,638 | 478,480 | -295,697 | -334,542 | -191,068 | -376,048 | 446,906 | 404,964 | 305,869 | 252,945 | 109,493 | -109,199 | -102,321 |
| Net Income Margin | -100.0% | - | 0.09* | 0.10* | 0.26* | 0.28* | 0.30* | 0.32* | 0.18* | 0.12* | 0.18* | -0.11* | -0.14* | -0.08* | -0.17* | 0.21* | - | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 648,597 | 969,941 | 801,630 | 760,347 | 759,134 | 749,488 | 741,458 | 668,475 | 764,913 | -124,599 | -100,302 | -12,002 | -128,424 | 710,656 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 7.1% | 6,208 | 5,798 | 5,841 | 5,510 | 5,319 | 5,054 | 4,933 | 4,199 | 3,905 | 3,661 | 3,561 | 3,307 | 3,212 | 2,752 | 3,427 | 3,215 | 2,948 | 2,754 | 2,646 | 2,520 | 2,397 |
| Current Assets | 7.4% | 4,264 | 3,972 | 4,093 | 3,821 | 3,626 | 3,288 | 3,119 | 2,924 | 2,620 | 2,450 | 2,360 | 2,159 | 2,078 | 1,716 | 2,481 | 2,320 | 2,059 | 1,905 | 1,832 | 1,700 | 1,598 |
| Cash Equivalents | 11.0% | 3,131 | 2,821 | 2,951 | 2,691 | 2,437 | 2,258 | 2,059 | 2,001 | 1,799 | 1,672 | 1,515 | 1,500 | 1,329 | 1,046 | 1,834 | 1,703 | 1,417 | 1,301 | 1,165 | 1,113 | 930 |
| Inventory | -12.2% | 36.00 | 41.00 | 42.00 | 46.00 | 55.00 | 35.00 | 28.00 | 21.00 | 17.00 | 17.00 | 16.00 | 17.00 | 16.00 | 14.00 | 11.00 | 7.00 | 7.00 | 7.00 | 7.00 | 6.00 | 6.00 |
| Net PPE | 1.0% | 749 | 742 | 739 | 716 | 721 | 729 | 724 | 687 | 661 | 595 | 560 | 498 | 454 | 410 | 378 | 347 | 339 | 338 | 320 | 301 | 268 |
| Goodwill | 0% | 156 | 156 | 156 | 156 | 156 | 156 | 156 | 156 | 156 | 156 | 156 | 156 | 156 | 156 | 156 | 156 | 156 | 156 | 156 | 156 | 156 |
| Liabilities | 9.9% | 1,468 | 1,335 | 1,471 | 1,284 | 1,234 | 1,191 | 1,163 | 1,050 | 969 | 934 | 950 | 917 | 868 | 815 | 828 | 792 | 700 | 669 | 720 | 717 | 664 |
| Current Liabilities | 11.2% | 1,119 | 1,006 | 1,157 | 1,007 | 927 | 886 | 854 | 743 | 660 | 624 | 631 | 606 | 557 | 503 | 513 | 462 | 367 | 365 | 425 | 422 | 368 |
| Shareholder's Equity | 6.2% | 4,741 | 4,463 | 4,370 | 4,227 | 4,085 | 3,863 | 3,770 | 3,149 | 2,936 | 2,728 | 2,611 | 2,391 | 2,345 | 1,938 | 2,598 | 2,423 | 2,247 | 2,086 | 1,926 | 1,803 | 1,733 |
| Retained Earnings | 49.0% | -211 | -415 | -437 | -465 | -578 | -739 | -777 | -1,341 | -1,523 | -1,672 | -1,726 | -1,876 | -1,861 | -2,151 | -1,430 | -1,541 | -1,670 | -1,775 | -1,877 | -1,946 | -1,976 |
| Additional Paid-In Capital | 1.4% | 4,926 | 4,857 | 4,792 | 4,721 | 4,689 | 4,626 | 4,567 | 4,509 | 4,477 | 4,421 | 4,353 | 4,277 | 4,218 | 4,102 | 4,044 | 3,973 | 3,926 | 3,870 | 3,814 | 3,759 | 3,719 |
| Shares Outstanding | 0.1% | 223 | 223 | 223 | 222 | 222 | 221 | 221 | 221 | 220 | 220 | 219 | 219 | 218 | 217 | 216 | 215 | 215 | 214 | 213 | 213 | 212 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 20.4% | 781 | 649 | 970 | 802 | 760 | 759 | 749 | 741 | 668 | 765 | -124 | -100 | -12.00 | -128 | 711 | 663 | 592 | 471 | 336 | 163 | 17.00 |
| Share Based Compensation | 4.1% | 206 | 198 | 188 | 184 | 181 | 179 | 183 | 180 | 181 | 183 | 178 | 175 | 174 | 169 | 167 | 162 | 157 | 153 | 148 | 145 | 142 |
| Cashflow From Investing | 5.6% | -85.30 | -90.35 | -78.54 | -123 | -128 | -164 | -207 | -244 | -226 | -220 | -269 | -196 | -169 | -171 | -87.45 | -93.52 | -123 | -82.46 | -86.42 | -193 | -206 |
| Cashflow From Financing | -97.2% | 0.00 | 3.00 | -0.79 | 11.00 | 6.00 | -6.56 | 6.00 | 9.00 | 29.00 | 82.00 | 72.00 | 89.00 | 91.00 | 44.00 | 46.00 | 20.00 | 20.00 | 17.00 | 15.00 | 14.00 | 666 |
INCY Income Statement
2023-06-30CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenues: | ||||
| Total revenues | $ 954,610 | $ 911,397 | $ 1,763,283 | $ 1,644,632 |
| Costs and expenses: | ||||
| Cost of product revenues (including definite-lived intangible amortization) | 68,326 | 50,636 | 125,148 | 93,250 |
| Research and development | 400,750 | 347,196 | 807,391 | 700,569 |
| Selling, general and administrative | 283,929 | 253,277 | 599,535 | 462,861 |
| Loss on change in fair value of acquisition-related contingent consideration | 8,374 | 3,313 | 14,570 | 9,695 |
| (Profit) and loss sharing under collaboration agreements | (549) | 2,544 | (1,911) | 7,286 |
| Total costs and expenses | 760,830 | 656,966 | 1,544,733 | 1,273,661 |
| Income from operations | 193,780 | 254,431 | 218,550 | 370,971 |
| Interest income and other, net | 42,668 | 522 | 75,541 | 1,782 |
| Interest expense | (655) | (678) | (1,124) | (1,358) |
| Unrealized gain (loss) on long term investments | 41,811 | (24,897) | 36,493 | (71,482) |
| Income before provision for income taxes | 277,604 | 229,378 | 329,460 | 299,913 |
| Provision for income taxes | 74,056 | 67,946 | 104,209 | 100,489 |
| Net income | $ 203,548 | $ 161,432 | $ 225,251 | $ 199,424 |
| Net income per share: | ||||
| Basic (in USD per share) | $ 0.91 | $ 0.73 | $ 1.01 | $ 0.90 |
| Diluted (in USD per share) | $ 0.90 | $ 0.72 | $ 1.00 | $ 0.89 |
| Shares used in computing net income per share: | ||||
| Basic (in shares) | 223,248 | 221,660 | 223,104 | 221,493 |
| Diluted (in shares) | 225,649 | 223,661 | 225,541 | 223,277 |
| Product revenues, net | ||||
| Revenues: | ||||
| Total revenues | $ 827,005 | $ 663,851 | $ 1,520,242 | $ 1,269,672 |
| Product royalty revenues | ||||
| Revenues: | ||||
| Total revenues | 127,605 | 117,546 | 243,041 | 239,960 |
| Milestone and contract revenues | ||||
| Revenues: | ||||
| Total revenues | $ 0 | $ 130,000 | $ 0 | $ 135,000 |
INCY Balance Sheet
2023-06-30CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 | [1] | ||
|---|---|---|---|---|---|
| Current assets: | |||||
| Cash and cash equivalents | $ 3,131,123 | $ 2,951,422 | |||
| Marketable securities—available-for-sale (amortized cost $294,371 and $292,580 as of June 30, 2023 and December 31, 2022, respectively; allowance for credit losses $0 as of June 30, 2023 and December 31, 2022) | 292,243 | 287,543 | |||
| Accounts receivable | 637,994 | 644,879 | |||
| Inventory | 35,937 | 41,995 | |||
| Prepaid expenses and other current assets | 167,136 | 167,011 | |||
| Total current assets | 4,264,433 | 4,092,850 | |||
| Restricted cash | 1,719 | 1,698 | |||
| Long term investments | 170,316 | 133,676 | |||
| Inventory | 142,048 | 78,964 | |||
| Property and equipment, net | 749,352 | 739,310 | |||
| Finance lease right-of-use assets, net | 25,631 | 26,298 | |||
| Other intangible assets, net | 134,954 | 129,219 | |||
| Goodwill | 155,593 | 155,593 | |||
| Deferred income tax asset | 532,507 | 457,941 | |||
| Other assets, net | 31,706 | 25,435 | |||
| Total assets | 6,208,259 | 5,840,984 | |||
| Current liabilities: | |||||
| Accounts payable | 155,538 | 277,546 | |||
| Accrued compensation | 111,708 | 138,761 | |||
| Accrued and other current liabilities | 810,852 | 701,053 | |||
| Finance lease liabilities | 3,166 | 3,179 | |||
| Acquisition-related contingent consideration | 37,509 | 36,538 | |||
| Total current liabilities | 1,118,773 | 1,157,077 | |||
| Acquisition-related contingent consideration | 179,491 | 184,462 | |||
| Finance lease liabilities | 29,491 | 30,083 | |||
| Other liabilities | 139,812 | 99,243 | |||
| Total liabilities | 1,467,567 | 1,470,865 | |||
| Commitments and contingencies | |||||
| Stockholders’ equity: | |||||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding | 0 | 0 | |||
| Common stock, $0.001 par value; 400,000,000 shares authorized; 223,338,330 and 222,746,719 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | 223 | 223 | |||
| Additional paid-in capital | 4,925,626 | 4,792,041 | |||
| Accumulated other comprehensive income | 26,806 | 15,069 | |||
| Accumulated deficit | (211,963) | (437,214) | |||
| Total stockholders’ equity | 4,740,692 | 4,370,119 | |||
| Total liabilities and stockholders’ equity | $ 6,208,259 | $ 5,840,984 | |||
| |||||
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.